ArticleOphthalmology and therapy2026
From Scalpel to Syringe: Intralesional Interleukin-2-Based Therapy is Effective for Locally Advanced Periocular Cutaneous Squamous Cell Carcinoma.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCutaneous squamous cell carcinoma (cSCC) is a common eyelid malignancy that is typically treated by surgical excision. Locally destructive periocular cSCC may not be amenable to surgery in cases where extensive resection would result in structural or functional compromise.
methodsWe report the first series of biopsy-confirmed periocular cSCC cases treated with intralesional interleukin-2 (IL-2)-based therapy.
resultsTreatment courses for five patients are summarized, with one representative case detailed here. A 74-year-old man presented with a large, painful, centrally pedunculated mass on the left upper eyelid, measuring 5.5 cm by 2.5 cm. Mass excisional biopsy and reconstruction revealed moderately differentiated invasive SCC involving deep and peripheral margins. Given the risks associated with further resection, the patient opted to pursue local immunotherapy. He received five doses of intralesional IL-2 every 2 weeks. The lesion was completely clinically cleared at 6 weeks, and there was no recurrence noted at 15-month follow-up.
conclusionLocal intralesional IL-2-based therapy may be a treatment option for periocular cSCC in cases that may result in significant functional or aesthetic compromise, or in those who have failed prior standard of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.